Cingulate Inc.
CINGCingulate Inc. in brief
Cingulate Inc. is a listed company in the Biotechnology industry, based in Kansas City, Kansas, USA. Its market value was $83 M on 28 October 2026, which makes it the 19,456th largest listed company in the world and the 3,622nd largest in the USA on this site. Shane J. Schaffer is its chief executive. Its shares trade under the symbol CING (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Cingulate Inc.
We are a biopharmaceutical company using our proprietary Precision Timed ReleaseTM drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder and anxiety, we are identifying and evaluating additional therapeutic areas where our PTR technology may be employed to develop future product candidates. Our PTR platform incorporates a proprietary Erosion Barrier Layer designed to allow for the release of drug substance at specific, pre-defined time intervals, unlocking the potential for once-daily, multi-dose tablets.
From the company's annual report filed with the US SEC: read the report
Cingulate Inc. timeline
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 9 December 2021; shares registered for exchange trading on 3 December 2021.
Events of Cingulate Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,529 (Dec 2022) · #5,575 (Jul 2023) · #4,557 (Jan 2024) · #2,048 (Mar 2026) · #3,613 (Aug 2026) · #3,671 (Oct 2026) · #3,626 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 33.0×
- Free cash flow yield
- -21.0%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -894.4%
- Liabilities / assets
- 83.3%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-20M | $-22M | — |
| Dec 2024 | — | — | $-16M | $-17M | — |
| Dec 2023 | — | — | $-23M | $-24M | — |
| Dec 2022 | — | — | $-18M | $-18M | — |
| Dec 2021 | — | — | $-21M | $-21M | — |
| Dec 2020 | — | — | $-7M | $-7M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-17M | $0M | $-17M | $-4.44 | — |
| Dec 2024 | $-18M | $0M | $-19M | $-10.86 | — |
| Dec 2023 | $-15M | $0M | $-15M | $-311.99 | — |
| Dec 2022 | $-16M | $0M | $-16M | $-29.35 | — |
| Dec 2021 | $-10M | $1M | $-11M | $-2.79 | — |
| Dec 2020 | $-7M | $0M | $-7M | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 10, 20268-KCurrent reportRegulation FD disclosure · Other events
- Oct 2, 20268-KCurrent reportDirectors or officers changed
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jul 23, 20268-KCurrent reportDirectors or officers changed
- Jul 14, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Jul 2, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Jun 16, 20268-KCurrent reportRegulation FD disclosure
- Jun 2, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 29, 2026DEF 14AProxy statement
- May 19, 20268-KCurrent reportDirectors or officers changed
- May 14, 202610-QQuarterly report · period to Mar 2026
Official filings of Cingulate Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-20 M
- Net income
- $-22 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $15 M
- Total liabilities
- $13 M
- Total equity
- $3 M
As of December-2025
Top 41 institutional investors in Cingulate Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 570,873 | 0 (0.00%) | 3.93% | $3 M | Nov 13, 2026 |
| 2 | Susquehanna International Group, LLP | 223,866 | New | 1.54% | $1 M | Nov 16, 2026 |
| 3 | Raymond James Financial Inc | 214,898 | +48,000 (+28.76%) | 1.48% | $1 M | Nov 12, 2026 |
| 4 | Renaissance Technologies LLC | 186,384 | +58,884 (+46.18%) | 1.28% | $1 M | Nov 12, 2026 |
| 5 | Citadel Advisors LLC | 176,930 | New | 1.22% | $1 M | Nov 16, 2026 |
| 6 | Marshall Wace, LLP | 160,380 | New | 1.10% | $1 M | Nov 13, 2026 |
| 7 | Kestra Advisory Services, LLC | 156,500 | +5,000 (+3.30%) | 1.08% | $1 M | Nov 2, 2026 |
| 8 | Geode Capital Management, LLC | 152,820 | +8,184 (+5.66%) | 1.05% | $1 M | Nov 6, 2026 |
| 9 | Bolton Securities Corporation | 139,000 | 0 (0.00%) | 0.96% | $1 M | Nov 12, 2026 |
| 10 | Chicago Partners Investment Group LLC | 110,737 | -77,692 (-41.23%) | 0.76% | $1 M | Oct 27, 2026 |
| 11 | North Star Investment Management Corp. | 100,000 | New | 0.69% | $0 M | Oct 27, 2026 |
| 12 | Vanguard Fiduciary Trust Co | 88,831 | +9,671 (+12.22%) | 0.61% | $0 M | Nov 13, 2026 |
| 13 | Simplex Trading, LLC | 70,978 | New | 0.49% | $0 M | Nov 4, 2026 |
| 14 | UBS Group AG | 68,970 | +43,023 (+165.81%) | 0.47% | $0 M | Nov 10, 2026 |
| 15 | BlackRock, Inc. | 54,506 | +1,376 (+2.59%) | 0.37% | $0 M | Nov 13, 2026 |
| 16 | State Street Corp | 52,188 | +4,300 (+8.98%) | 0.36% | $0 M | Nov 12, 2026 |
| 17 | BCV Asset Management Inc. | 51,200 | 0 (0.00%) | 0.35% | $0 M | Nov 6, 2026 |
| 18 | Captrust Financial Advisors | 42,123 | New | 0.29% | $0 M | Nov 12, 2026 |
| 19 | Northern Trust Corp | 35,226 | +105 (+0.30%) | 0.24% | $0 M | Nov 16, 2026 |
| 20 | Prospera Financial Services Inc | 32,250 | +2,350 (+7.86%) | 0.22% | $0 M | Nov 4, 2026 |
| 21 | Quantum Private Wealth, LLC | 30,000 | 0 (0.00%) | 0.21% | $0 M | Oct 20, 2026 |
| 22 | Bank Of America Corp /de/ | 27,329 | New | 0.19% | $0 M | Nov 16, 2026 |
| 23 | Mariner, LLC | 23,140 | +1,859 (+8.74%) | 0.16% | $0 M | Nov 12, 2026 |
| 24 | Jane Street Group, LLC | 21,620 | -7,258 (-25.13%) | 0.15% | $0 M | Nov 12, 2026 |
| 25 | Spark Investment Management LLC | 20,400 | New | 0.14% | $0 M | Nov 13, 2026 |
Show all 41: investors 26 to 41
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | PKS Advisory Services, LLC | 11,500 | 0 (0.00%) | 0.08% | $0 M | Oct 26, 2026 |
| 27 | Vanguard Global Advisers, LLC | 4,743 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 28 | Morgan Stanley | 3,924 | -339 (-7.95%) | 0.03% | $0 M | Nov 13, 2026 |
| 29 | Group One Trading LLC | 3,672 | New | 0.03% | $0 M | Nov 10, 2026 |
| 30 | Barclays PLC | 3,130 | +1,564 (+99.87%) | 0.02% | $0 M | Nov 6, 2026 |
| 31 | Root Financial Partners, LLC | 2,500 | New | 0.02% | $0 M | Oct 21, 2026 |
| 32 | Jones Financial Companies Lllp | 2,364 | +364 (+18.20%) | 0.02% | $0 M | Nov 13, 2026 |
| 33 | Wells Fargo & Company/mn | 2,342 | +1,342 (+134.20%) | 0.02% | $0 M | Nov 16, 2026 |
| 34 | Harbour Investments, Inc. | 2,275 | New | 0.02% | $0 M | Nov 9, 2026 |
| 35 | IFP Advisors, Inc | 2,000 | 0 (0.00%) | 0.01% | $0 M | Oct 16, 2026 |
| 36 | Tower Research Capital LLC (TRC) | 614 | +140 (+29.54%) | 0.00% | $0 M | Nov 16, 2026 |
| 37 | Royal Bank Of Canada | 295 | New | 0.00% | $0 M | Nov 16, 2026 |
| 38 | Rialto Wealth Management, LLC | 102 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 39 | Caitong International Asset Management Co., Ltd | 8 | New | 0.00% | $0 M | Oct 29, 2026 |
| 40 | FMR LLC | 6 | New | 0.00% | $0 M | Nov 10, 2026 |
| 41 | SBI Securities Co., Ltd. | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
Mutual funds holding Cingulate Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 394,555 | $2 M | 2.7% | <0.01% | +86% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 160,396 | $1 M | 1.1% | <0.01% | +75% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 42,839 | $0 M | 0.29% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 27,990 | $0 M | 0.19% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 22,533 | $0 M | 0.15% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 10,246 | $0 M | 0.07% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 10,991 | $0 M | 0.08% | <0.01% | +40% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 8,474 | $0 M | 0.06% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 5,676 | $0 M | 0.04% | <0.01% | +1.4% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,871 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 246 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 11 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Cingulate Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Raul R. SilvaEVP and CSO | Grant or award | +4,526 | — | — | 6,473 | Form 4 |
| filed | Matthew BramsEVP and Chief Medical Officer | Grant or award | +4,526 | — | — | 9,182 | Form 4 |
| filed | Nilay Dahyabhai PatelEVP, CLO and CCO | Grant or award | +5,475 | — | — | 5,475 | Form 4 |
| filed | Jennifer L. CallahanEVP and CFO | Grant or award | +15,329 | — | — | 20,388 | Form 4 |
| filed | Shane J. SchafferChief Executive Officer, Director | Grant or award | +6,862 | — | — | 7,035 | Form 4 |
| filed | Nilay Dahyabhai PatelEVP, CLO and CCO | Shares withheld for tax | -2,086 | — | — | 3,389 | Form 4 |
| filed | Matthew BramsEVP and Chief Medical Officer | Shares withheld for tax | -1,025 | — | — | 8,157 | Form 4 |
| filed | Jennifer L. CallahanEVP and CFO | Shares withheld for tax | -6,427 | — | — | 13,961 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Cingulate Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-06-02 13:34 UTC, code LUDP, resumed 13:39 UTC
- 2026-06-02 11:55 UTC, code T3, resumed 12:30 UTC
Fails to deliver
- : 1,460 shares at $5.53
- : 3,646 shares at $4.36
- : 35 shares at $4.84
- : 1 shares at $4.75
- : 800 shares at $4.76
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Cingulate Inc. scorecard#
Passes 1 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median33.0×Price to book 33.0× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-21.0%Free cash flow is -21.0% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-4.44 vs -10.86Diluted EPS -4.44 in fiscal 2025 against -10.86 the year before (report's currency).
- ✗Net income higher than five years earlier-$22 M-$22 M in fiscal 2025 against -$7 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$22 MNet income -$22 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-450.4%-450.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.2×Current ratio 1.16 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-22.2×Operating income -22.2 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year231.5%Diluted shares up 231.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Cingulate Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | 9.8+3.5%— | 9.4−39.0%— | 15+72.2%— | 9.0+7.0%— | 8.4+65.1%— | 5.1—— | |
| General and administrative | 10+63.9%— | 6.2−14.7%— | 7.3−14.6%— | 8.5−30.7%— | 12+517%— | 2.0—— | |
| Operating income | −20—— | −16—— | −23—— | −18—— | −21—— | −7.1—— | |
| Interest expense and finance costs | 0.9+3455%— | 0.0−96.8%— | 0.8+170%— | 0.3+775%— | 0.0−38.8%— | 0.1—— | |
| Net interest income | −1.4−1472%— | 0.1—— | — | — | — | — | |
| Other non-operating income (expense) | — | 0.1—— | −0.8—— | −0.2—— | −0.0—— | −0.1—— | |
| Income before tax | −22—— | −17r−16—— | −24—— | −18—— | −21—— | −7.2—— | |
| Net income attributable to shareholders | −22—— | −17r−16—— | −24—— | −18—— | −21—— | −7.2—— | |
| Earnings per share, basic | -4.44—— | -10.86r-10.20—— | -311.99r-26.00—— | -29.35r-1.56—— | -2.79—— | — | |
| Earnings per share, diluted | -4.44—— | -10.86r-10.20—— | -311.99r-26.00—— | -29.35—— | -2.79—— | — | |
| Shares, weighted average (basic) | 5.1+232%— | 1.5+1921%— | 0.1r0.9−87.5%— | 0.6r11−91.9%— | 7.4—— | — | |
| Shares, weighted average (diluted) | 5.1+232%— | 1.5+1921%— | 0.1r0.9−87.5%— | 0.6−91.9%— | 7.4—— | — | |
| Balance sheet | |||||||
| Cash and cash equivalents | 11−10.3%72.7% | 12+23197%82.2% | 0.1−99.0%1.5% | 5.4−67.5%47.0% | 16+1277%72.1% | 1.2—20.7% | |
| Short-term investments | — | — | — | — | 0.00.0%0.0% | 0.0—0.0% | |
| Receivables | — | — | 0.0—0.4% | — | — | — | |
| Other current assets | 1.0+147%6.9% | 0.4−17.3%2.8% | 0.5−77.6%14.7% | 2.3+34.2%20.0% | 1.7+286%7.4% | 0.4—7.6% | |
| Current assets | 12−5.2%79.7% | 13+2088%85.2% | 0.6−92.6%16.6% | 7.9−58.3%69.0% | 19+955%82.5% | 1.8—30.9% | |
| Property, plant and equipment | 1.7−18.0%11.5% | 2.1−17.3%14.2% | 2.5−12.4%72.9% | 2.9−7.6%25.5% | 3.1+3.5%13.7% | 3.0—52.5% | |
| Right-of-use (leased) assets | 1.3+1252%8.9% | 0.1−73.0%0.7% | 0.4−41.8%10.5% | 0.6−26.6%5.5% | 0.9−10.4%3.8% | 1.0—16.6% | |
| Total assets | 15+1.4%100% | 15+326%100% | 3.5−69.4%100% | 11−50.2%100% | 23+295%100% | 5.8—100% | |
| Accounts payable | 2.0+60.3%13.5% | 1.3−75.6%8.5% | 5.2r5.2+582%149% | 0.8+188%6.7% | 0.3−72.9%1.2% | 1.0—16.8% | |
| Current liabilities | 10+107%68.4% | 5.0−51.4%33.4% | 10+45.8%293% | 7.0+496%61.5% | 1.2−65.0%5.1% | 3.4—58.1% | |
| Lease liabilities (non-current) | 1.1—7.3% | — | 0.1−73.3%3.7% | 0.5−41.0%4.3% | 0.8−21.7%3.6% | 1.1—18.3% | |
| Non-current liabilities | 2.3−7.6%14.9% | 2.4+1704%16.4% | 0.1−73.5%3.9% | 0.5−41.1%4.5% | 0.9—3.8% | — | |
| Total liabilities | 13+69.6%83.4% | 7.4−28.5%49.8% | 10+37.7%297% | 7.5+268%66.0% | 2.0−54.6%8.9% | 4.5—77.7% | |
| Retained earnings | −132—−878% | −110r−108—−740% | −93—−2662% | −69—−609% | −52—−226% | −31—−536% | |
| Shareholders' equity | 2.5−66.3%16.6% | 7.5—50.2% | −6.9−277%−197% | 3.9−81.4%34.0% | 21+1513%91.1% | 1.3r1.3—22.3% | |
| Total liabilities and equity | 15+1.4%100% | 15+326%100% | 3.5−69.4%100% | 11−50.2%100% | 23+295%100% | 5.8—100% | |
| Shares outstanding | 7.3+113%— | 3.4+3397%— | 0.1r1.2−83.9%— | 0.6r11−94.7%— | 11—— | — | |
| Cash-flow statement | |||||||
| Share-based compensation | 1.5+53.1%— | 1.0+22.5%— | 0.8+1.5%— | 0.8+1727%— | 0.0—— | — | |
| Cash from operating activities | −17—— | −18—— | −15—— | −16—— | −10—— | −6.8—— | |
| Capital expenditure | −0.2—— | −0.2—— | −0.2—— | −0.2—— | −0.8—— | −0.4—— | |
| Cash from investing activities | −0.2—— | −0.2—— | −0.2—— | −0.2—— | −0.8—— | −0.4—— | |
| Shares issued | 10−60.8%— | 26+271%— | 7.0—— | — | 20—— | — | |
| Cash from financing activities | 16−47.6%— | 31+210%— | 10.0+103%— | 4.9−81.5%— | 27+233%— | 8.0—— | |
| Change in cash | −1.3−110%— | 12—— | −5.3—— | −11−173%— | 15—— | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 8.6−29.1%— | 2.9+2.2%— | 1.5−45.0%— | 2.2−1.7%— | 2.0*−53.8%— | 2.8+99.4%— | 2.7+43.6%— | 2.2+23.0%— | 4.3*−13.2%— | 1.4—— | 1.9—— | 1.8—— | 5.0*—— | |
| Selling, general and administrative | — | 4.6+45.5%— | 3.9+102%— | — | — | 3.1—— | 1.9—— | — | — | — | — | — | — | |
| General and administrative | — | — | — | 5.7+287%— | 3.6*+90.7%— | 3.1+69.8%— | 1.9+47.1%— | 1.5+30.0%— | 1.9*+3.7%— | 1.9—— | 1.3—— | 1.1—— | 1.8*—— | |
| Operating income | −26—— | −7.5—— | −5.4—— | −7.9—— | −5.6*—— | −6.0—— | −4.6—— | −3.7—— | −6.2*—— | −3.3—— | −3.2—— | −2.9—— | −6.8*—— | |
| Interest expense and finance costs | 1.1—— | 0.2−5.0%— | 0.2+10.6%— | 0.3+66.1%— | 0.3*—— | 0.2—— | 0.2—— | 0.2+571%— | — | — | — | 0.0—— | 0.1*—— | |
| Net interest income | −1.4—— | −0.2—— | −0.1—— | −0.5—— | −0.6*—— | −0.6—— | −0.1—— | −0.1—— | — | — | −0.0—— | −0.0—— | — | |
| Other non-operating income (expense) | — | — | — | — | — | −0.6−1235%— | −0.1—— | −0.1—— | 0.1*—— | 0.1—— | −0.0—— | −0.0—— | −0.1*—— | |
| Income before tax | −29—— | −7.7—— | −5.9—— | −9.3—— | −6.3*—— | −7.3—— | −5.0r−4.8—— | −3.9r−3.8—— | −6.2r−6.1*—— | −4.1r−3.2—— | −3.2—— | −3.0—— | −6.9*—— | |
| Net income attributable to shareholders | −29—— | −7.7—— | −5.9—— | −9.3—— | −6.3*—— | −7.3—— | −5.0r−4.8—— | −3.9r−3.8—— | −6.2r−6.1*—— | −4.1r−3.2—— | −3.2r−3.2—— | −3.0—— | −6.9*—— | |
| Earnings per share, basic | — | -0.53—— | -0.45—— | -0.95—— | — | -1.35—— | -1.14r-1.09—— | -1.06r-1.04—— | — | -2.34r-1.83—— | -5.47—— | -7.21r-0.60—— | — | |
| Earnings per share, diluted | — | -0.53—— | -0.45—— | -0.95—— | — | -1.35—— | -1.14r-1.09—— | -1.06r-1.04—— | — | -2.34r-1.83—— | -5.47—— | -7.21r-0.60—— | — | |
| Shares, weighted average (basic) | 15+168%— | 15+168%— | 13+200%— | 9.8+168%— | — | 5.4+207%— | 4.4+649%— | 3.6+785%— | — | 1.8—— | 0.6—— | 0.4r4.9—— | — | |
| Shares, weighted average (diluted) | 15+168%— | 15+168%— | 13+200%— | 9.8+168%— | — | 5.4+207%— | 4.4+649%— | 3.6+785%— | — | 1.8—— | 0.6—— | 0.4r4.9—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 23—82.4% | 23+279%82.4% | 28+219%85.9% | 26+172%83.9% | 11−10.3%72.7% | 6.1−39.1%58.2% | 8.9+2236%66.1% | 9.5+755%76.3% | 12+23197%82.2% | 10—73.9% | 0.4—7.4% | 1.1—20.3% | 0.1—1.5% | |
| Receivables | — | — | — | — | — | — | — | — | — | 0.0—0.0% | 1.6—31.5% | — | 0.0—0.4% | |
| Other current assets | 2.1—7.4% | 2.1+61.0%7.4% | 1.8+35.6%5.3% | 2.0+108%6.4% | 1.0+147%6.9% | 1.3−0.4%12.3% | 1.3+151%9.7% | 0.9−41.4%7.6% | 0.4−17.3%2.8% | 1.3—9.6% | 0.5—10.1% | 1.6—29.3% | 0.5—14.7% | |
| Current assets | 25—89.9% | 25+241%89.9% | 30+195%91.4% | 28+166%90.4% | 12−5.2%79.7% | 7.4−34.5%70.7% | 10+306%75.9% | 11+285%84.2% | 13+2088%85.2% | 11—83.5% | 2.5—49.1% | 2.7—49.6% | 0.6—16.6% | |
| Property, plant and equipment | 1.7—5.9% | 1.7−1.2%5.9% | 1.6−9.1%4.9% | 1.7−14.1%5.4% | 1.7−18.0%11.5% | 1.7−18.1%16.1% | 1.8−24.2%13.4% | 1.9−21.3%15.6% | 2.1−17.3%14.2% | 2.1—15.2% | 2.4—46.3% | 2.5—44.8% | 2.5—72.9% | |
| Right-of-use (leased) assets | 1.2—4.1% | 1.2−16.6%4.1% | 1.2−15.5%3.7% | 1.3+4982%4.2% | 1.3+1252%8.9% | 1.4+720%13.3% | 1.4+508%10.7% | 0.0−91.7%0.2% | 0.1−73.0%0.7% | 0.2—1.3% | 0.2—4.6% | 0.3—5.5% | 0.4—10.5% | |
| Total assets | 28—100% | 28+168%100% | 33+146%100% | 31+147%100% | 15+1.4%100% | 11−22.5%100% | 13+163%100% | 12+127%100% | 15+326%100% | 14—100% | 5.1—100% | 5.5—100% | 3.5—100% | |
| Accounts payable | 1.6—5.7% | 1.6+83.9%5.7% | 2.0+128%6.0% | 2.7+212%8.7% | 2.0+60.3%13.5% | 0.9−4.4%8.2% | 0.9−34.3%6.5% | 0.9+15.9%6.9% | 1.3−75.6%8.5% | 0.9—6.7% | 1.3—25.9% | 0.7—13.4% | 5.2r5.2—149% | |
| Current liabilities | 6.5—23.0% | 6.5+10.2%23.0% | 8.6+28.2%26.1% | 11+95.2%35.5% | 10+107%68.4% | 5.9+281%55.9% | 6.7+230%50.0% | 5.6+150%45.0% | 5.0−51.4%33.4% | 1.5—11.4% | 2.0—39.9% | 2.2—40.9% | 10—293% | |
| Lease liabilities (non-current) | 0.9—3.2% | 0.9−22.7%3.2% | 1.0−20.9%2.9% | 1.0—3.4% | 1.1—7.3% | 1.2—11.1% | 1.2—9.1% | — | — | — | — | 0.0—0.6% | 0.1—3.7% | |
| Non-current liabilities | 0.9—3.2% | 0.9−22.7%3.2% | 1.0−20.9%2.9% | 1.0+12.1%3.4% | 2.3−7.6%14.9% | 1.2—11.1% | 1.2—9.1% | 0.9+2687%7.4% | 2.4+1704%16.4% | — | — | 0.0—0.6% | 0.1—3.9% | |
| Total liabilities | 7.4—26.2% | 7.4+4.8%26.2% | 9.6+20.6%29.0% | 12+83.5%38.9% | 13+69.6%83.4% | 7.0+357%67.0% | 8.0+289%59.1% | 6.5+187%52.4% | 7.4−28.5%49.8% | 1.5—11.4% | 2.0—39.9% | 2.3—41.5% | 10—297% | |
| Retained earnings | −155—−552% | −155—−552% | −148—−446% | −142—−459% | −132—−878% | −126—−1199% | −117—−869% | −112—−901% | −110r−108—−740% | −102—−754% | −99—−1933% | −96—−1746% | −93—−2662% | |
| Shareholders' equity | 21—73.8% | 21+498%73.8% | 23+326%71.0% | 19+218%61.1% | 2.5−66.3%16.6% | 3.5−71.1%33.0% | 5.5+78.7%40.9% | 5.9+84.4%47.6% | 7.5—50.2% | 12—88.6% | 3.1—60.1% | 3.2—58.5% | −6.9—−197% | |
| Total liabilities and equity | 28—100% | 28+168%100% | 33+146%100% | 31+147%100% | 15+1.4%100% | 11−22.5%100% | 13+163%100% | 12+127%100% | 15+326%100% | 14—100% | 5.1—100% | 5.5—100% | 3.5—100% | |
| Shares outstanding | 15—— | 15+147%— | 14+184%— | 12+211%— | 7.3+113%— | 6.0+96.4%— | 4.9+526%— | 3.8−23.6%— | 3.4+3397%— | 3.0—— | 0.8—— | 5.0—— | 0.1r1.2—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 2.1+73.1%— | 0.7*+23.7%— | 0.4*+93.3%— | 0.6+65.8%— | 0.4*+540%— | 0.6*+50.5%— | 0.2*−50.3%— | 0.4+117%— | 0.1*−61.0%— | 0.4*—— | 0.4*—— | 0.2—— | 0.2*—— | |
| Cash from operating activities | −24—— | −7.4*—— | −5.9*—— | −6.9—— | −3.6*—— | −4.2*—— | −4.8*—— | −4.6—— | −4.1*—— | −3.9*—— | −1.7*—— | −8.7—— | −2.6*—— | |
| Capital expenditure | −0.4—— | −0.1*—— | −0.1*—— | −0.1—— | −0.2*—— | 0*—— | — | — | −0.2*—— | — | −0.1*—— | −0.1—— | −0.2*—— | |
| Cash from investing activities | −0.4—— | −0.1*—— | −0.1*—— | −0.1—— | −0.2*—— | 0*−100%— | — | — | −0.2*—— | 0.1*—— | −0.1*—— | −0.1—— | −0.2*—— | |
| Shares issued | 37+307%— | 3.2*+121%— | 9.1*+118%— | 22+1041%— | 2.6*+73.8%— | 1.5*−89.1%— | 4.2*+285%— | 1.9−80.6%— | 1.5*+81.8%— | 13*—— | 1.1*—— | 9.9—— | 0.8*—— | |
| Cash from financing activities | 41+194%— | 2.2*+53.7%— | 8.5*+103%— | 22+1044%— | 8.6*+33.2%— | 1.5*−89.1%— | 4.2*+287%— | 1.9−80.6%— | 6.4*+691%— | 13*—— | 1.1*—— | 9.9—— | 0.8*—— | |
| Change in cash | 17—— | −5.2*—— | 2.5*—— | 15—— | 4.8*+123%— | −2.8*−129%— | −0.6*—— | −2.7−354%— | 2.2*—— | 9.7*—— | −0.7*—— | 1.1—— | −1.9*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Cingulate Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 11 · Material agreement 3 · New debt 1 · Unregistered share sale 6 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officersUnregistered share sale | 8-K | |
| Unregistered share sale | 8-K | |
| Material agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Unregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Shareholder vote | 8-K | |
| Unregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Unregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 2, 2026
How Cingulate Inc. compares in Biotechnology
- Market cap$83 M · higher than 33% of 726
- Price / book33.0× · lower than 5% of 534
- FCF yield-21.0% · higher than 43% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Cingulate Inc.🇺🇸 | $83 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Cingulate Inc.? Verify and update this profile — free
Show Cingulate Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.